Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1

Inclusion Criteria: 1. written informed consent; 2. ≥18 years of age; 3. a bacterial infection of the skin with a lesion size area of at least 75 cm2; 4. a major cutaneous abscess, cellulitis/erysipelas, and/or wound infections; 5. the presence of purulent or seropurulent drainage or at least three signs and symptoms of infection (discharge, erythema, swelling, warmth, or pain). Exclusion Criteria: 1. severely impaired arterial blood supply such that amputation of the infected anatomical site is likely; 2. infected diabetic foot ulcers; 3. infected decubitus ulcers; 4. necrotizing fasciitis or gangrene; 5. uncomplicated skin or skin structure infection; 6. infections associated with a prosthetic device; 7. suspected or confirmed osteomyelitis; 8. conditions requiring systemic anti-microbial treatment, prophylaxis, or suppression therapy.